Immunocore, a Milton, England-headquartered biotechnology company focused on immunotherapy, has received funding from the Bill & Melinda Gates Foundation to support the development of Immunocore’s soluble T-Cell Receptor (TCR)-based therapeutics for infectious diseases.

The Bill & Melinda Gates Foundation will invest up to $40 million in Immunocore to support development of Immunocore’s ImmTAV (Immune mobilizing monoclonal TCRs Against Virus) and ImmTAB (Immune mobilizing monoclonal TCRs Against Bacteria) therapeutics. The collaboration will discover and develop ImmTAV and ImmTAB molecules for treating tuberculosis and human immunodeficiency virus. Immunocore will also continue expanding its platform technology to enable therapeutics with broad coverage of the affected disease population.

The investment by the Bill & Melinda Gates Foundation was made as part of its program-related investments strategy, which aims to stimulate private sector-driven innovation, encourage market-driven efficiencies, and attract external capital to priority global health and development initiatives.

Source: Immunocore